UFP Technologies
UFPT on Nasdaq. Surgical & medical instruments & apparatus. Market value $2.4bn.
Price checks use the past 12 months to June 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.
Cash flow or capital spending isn't reported, so free cash flow is unknown.
Should I look at this?
Good business, but not cheap right now
Why it could be worth it
See cheaper Health care stocks on the list
This is not advice. Check the numbers below.
We could not compute this from the filings.
You pay 25.5 years of operating profit for the business. The average large US company costs around 18.
Each dollar kept in the business earns 14 cents a year. Above 10 is good.
Quality score: 98 of 100. Price score: 42 of 100. Our list needs 70 on quality and 60 on price.
$302.87 a share, 74% above its 1-year low
Over the past year the price has ranged from $173.86 to $338.71.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $206m | $354m | $400m | $504m | $603m |
| Operating margin | |||||
| Operating margin | 10.3% | 15.7% | 14.4% | 16.0% | 15.3% |
| Debt to equity | |||||
| Debt to equity | 0.39 | 0.23 | 0.11 | 0.55 | 0.32 |
| Shares outstanding | |||||
| Shares outstanding | 0.01bn | 0.01bn | 0.01bn | 0.01bn | 0.01bn |
Health checks
- Free cash flow positive4 of 4 years
- Accounting looks honest (Beneish)Nothing unusual
- Financial strength (Piotroski)7 of 9
- Profit backed by cash (accruals)Yes
- Debt0.32× equity
- Revenue growth, five yearsStrong, 27.4% a year
- Buying back its own sharesRoughly flat
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $174 million last quarter, up 15% on a year ago.
- Profit: $21 million, up 21% on a year ago.
- It keeps 15 cents of each $1 of sales as operating profit, down from 16 cents a year earlier.
- About the same number of shares as a year ago.
- Debt is $108 million more than cash, down from $149 million a year ago.
- Sales grew on a year ago in each of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $145m |
| December 2024 | $144m |
| March 2025 | $148m |
| June 2025 | $151m |
| September 2025 | $155m |
| December 2025 | $149m |
| March 2026 | $154m |
| June 2026 | $174m |
| Quarter to | Amount |
|---|---|
| September 2024 | $16m |
| December 2024 | $16m |
| March 2025 | $17m |
| June 2025 | $17m |
| September 2025 | $16m |
| December 2025 | $18m |
| March 2026 | $17m |
| June 2026 | $21m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 27 February 2026
- Next quarterly (estimated, 10-Q)
- 5 November 2026
Who owns it
2 long-term investors we follow own it, down from 3 last quarter. 279 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Diamond Hill Capital ManagementRic Dillon (founder) | $15m | 0.1% | Added |
| Royce & AssociatesChuck Royce | $12m | <0.1% | Added |
Sold out this quarter
Largest holders overall
- BlackRock$303mAdded
- Congress Asset Management$182mAdded
- Wasatch Advisors LP$181mCut
- Neuberger Berman Group$142mAdded
- Price T Rowe Associates$95mAdded
- Boston Trust Walden$89mAdded
- Vanguard Capital Management$87m
- State Street$83mAdded
- American Century Companies$74mAdded
- UBS Group AG$68mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
5 investors own more than 5%.
- Wasatch Advisors LPPassive investor8.8%−1.3 ptsSince 30 June 2026
- Neuberger Berman Group LLCPassive investorat least 6.9%+2.4 pts(filed with 1 related holder)Since 30 June 2026
- CONGRESS ASSET MANAGEMENT COPassive investor5.4%Since 31 March 2026
- Vanguard Capital ManagementPassive investor5.0%Since 30 June 2026
- Neuberger Berman Equity FundsPassive investorat least 2.9%(filed with 1 related holder)Since 31 March 2025
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
Wasatch Advisors LP Passive investor | 8.8%−1.3 pts | 30 June 2026 | |
Neuberger Berman Group LLC Passive investor | at least 6.9%+2.4 pts (filed with 1 related holder) | 30 June 2026 | |
CONGRESS ASSET MANAGEMENT CO Passive investor | 5.4% | 31 March 2026 | |
Vanguard Capital Management Passive investor | 5.0% | 30 June 2026 | |
Neuberger Berman Equity Funds Passive investor | at least 2.9% (filed with 1 related holder) | 31 March 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 7 sold $14m.
- KOZIN MARC DDirectorSold
- Date
- 25 August 2026
- Shares
- 7,000
- Price
- $304.50
- Value
- $2m
- Hudson SymeriaDirectorSold
- Date
- 18 August 2026
- Shares
- 298
- Price
- $319.11
- Value
- $95,095
- Hudson SymeriaDirectorSold
- Date
- 14 August 2026
- Shares
- 1,926
- Price
- $324.58
- Value
- $625,141
- FELDMANN CYNTHIA LDirectorSold
- Date
- 13 August 2026
- Shares
- 1,000
- Price
- $324.26
- Value
- $324,260
- BAILLY R JEFFREYExecutive Chairman, DirectorSold
- Date
- 10 August 2026
- Shares
- 13,011
- Price
- $316.13
- Value
- $4m
- BAILLY R JEFFREYExecutive Chairman, DirectorSold
- Date
- 7 August 2026
- Shares
- 5,013
- Price
- $317.87
- Value
- $2m
- BAILLY R JEFFREYExecutive Chairman, DirectorSold
- Date
- 6 August 2026
- Shares
- 10,682
- Price
- $318.63
- Value
- $3m
- Holt JasonVice PresidentSold
- Date
- 6 August 2026
- Shares
- 1,100
- Price
- $317.00
- Value
- $348,700
- FELDMANN CYNTHIA LDirectorSold
- Date
- 12 June 2026
- Shares
- 1,200
- Price
- $239.29
- Value
- $287,149
- CROTEAU DANIEL CDirectorSold
- Date
- 12 May 2026
- Shares
- 2,864
- Price
- $221.71
- Value
- $634,977
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 25 August 2026 | KOZIN MARC D Director | Sold | 7,000 | $304.50 | $2m |
| 18 August 2026 | Hudson Symeria Director | Sold | 298 | $319.11 | $95,095 |
| 14 August 2026 | Hudson Symeria Director | Sold | 1,926 | $324.58 | $625,141 |
| 13 August 2026 | FELDMANN CYNTHIA L Director | Sold | 1,000 | $324.26 | $324,260 |
| 10 August 2026 | BAILLY R JEFFREY Executive Chairman, Director | Sold | 13,011 | $316.13 | $4m |
| 7 August 2026 | BAILLY R JEFFREY Executive Chairman, Director | Sold | 5,013 | $317.87 | $2m |
| 6 August 2026 | BAILLY R JEFFREY Executive Chairman, Director | Sold | 10,682 | $318.63 | $3m |
| 6 August 2026 | Holt Jason Vice President | Sold | 1,100 | $317.00 | $348,700 |
| 12 June 2026 | FELDMANN CYNTHIA L Director | Sold | 1,200 | $239.29 | $287,149 |
| 12 May 2026 | CROTEAU DANIEL C Director | Sold | 2,864 | $221.71 | $634,977 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
What could go wrong
- It isn't cheap on profits: 25.5× operating profit.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.